醋酸甲羟孕酮104毫克/0.65毫升皮下注射后的体重变化
Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
作者信息
Westhoff Carolyn, Jain John K, Milsom Ian, Ray Amrit
机构信息
Department of Obstetrics and Gynecology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA, and Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg, Sweden.
出版信息
Contraception. 2007 Apr;75(4):261-7. doi: 10.1016/j.contraception.2006.12.009. Epub 2007 Feb 23.
INTRODUCTION
The study was conducted to assess the impact of depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL (DMPA-SC 104) on body weight.
METHODS
Changes in weight from pretreatment were analyzed using data from two 1-year, noncomparative trials of DMPA-SC 104 (North/South American, N=722; European/Asian, N=1065) and a 3-year, randomized study (SC/IM) comparing DMPA-SC 104 (N=266) with the DMPA intramuscular injection 150 mg/mL (DMPA-IM 150). For each study, additional analyses were conducted for changes in body weight by age (<25, 25 to 35 and >35 years) and body mass index (BMI) (<or=25, >25 to <or=30 and >30 kg/m2) subgroups.
RESULTS
In both 1-year trials, the mean (+/-SD) weight gain at month 12 was <2 kg [1.7 kg (+/-4.5 SD) in the Americas trial and 1.4 kg (+/-3.6 SD) in the Europe/Asia trial]. In the SC/IM trial, mean weight changes were similar between DMPA-SC 104 and DMPA-IM 150 groups, with mean (+/-SD) gains at month 36 of 4.5+/-8.5 and 5.8+/-8.7 kg, respectively. Similar differences in weight gain were observed by age or baseline BMI in all studies.
CONCLUSION
DMPA-SC 104 was associated with modest weight gain in most women.
引言
本研究旨在评估醋酸甲羟孕酮皮下注射104毫克/0.65毫升（DMPA-SC 104）对体重的影响。
方法
利用两项为期1年的DMPA-SC 104非对照试验（北美/南美，N = 722；欧洲/亚洲，N = 1065）以及一项为期3年的比较DMPA-SC 104（N = 266）与醋酸甲羟孕酮肌肉注射150毫克/毫升（DMPA-IM 150）的随机研究（皮下/肌肉注射）的数据，分析自治疗前起的体重变化。对于每项研究，还按年龄（<25岁、25至35岁和>35岁）和体重指数（BMI）（≤25、>25至≤30和>30千克/平方米）亚组对体重变化进行了额外分析。
结果
在两项为期1年的试验中，第12个月时的平均（±标准差）体重增加均<2千克[美洲试验中为1.7千克（±4.5标准差），欧洲/亚洲试验中为1.4千克（±3.6标准差）]。在皮下/肌肉注射试验中，DMPA-SC 104组和DMPA-IM 150组的平均体重变化相似，第36个月时的平均（±标准差）体重增加分别为4.5±8.5千克和5.8±8.7千克。在所有研究中，按年龄或基线BMI观察到的体重增加差异相似。
结论
大多数女性使用DMPA-SC 104后体重有适度增加。
Zotero 插件